NCT00980395 · REGISTRY CONDITION SEARCH

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-12-30

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with cladribine and rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine and rituximab works in treating patients with advanced mantle cell lymphoma or indolent lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival at 2 Years

→

outcome · POSTED

Overall Survival at 2 Years

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

Partial Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Voluntary consent before performance of any study-related procedure * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control * Male subject agrees to use an acceptable method for contraception for the duration of the study. * Biopsy-proven mantle cell, marginal zone, lymphoplasmacytic, small lymphocytic lymphoma, or follicular lymphoma * CD20-positive disease * Patients with marginal zone, lymphoplasmacytic, small lymphocytic, or follicular lymphoma - at least one criterion for initiation of treatment must be met: * Symptomatic disease * Cytopenia related to lymphoma * Leukemic phase (\> 5,000 malignant lymphocytes/µl) * Mass over 5 cm in greatest diameter * For lymphoplasmacytic lymphoma: additional treatment criteria are serum viscosity ≥ 4 cp, serum monoclonal protein \> 5 g/L, concurrent primary systemic AL amyloidosis, cold agglutinin disease * Age over 18 * Prior treatment with bortezomib and/or rituximab is acceptable * For follicular lymphoma only, at least one prior treatment Exclusion Criteria: * Platelet count of \< 100 X10 /L within 14 days before enrollment, unless due to bone marrow infiltration with lymphoma, or due to autoimmune thrombocytopenia because of lymphoma. * Patient has an absolute neutrophil count of \< 1.0 X 10/L within 14 days before registration, unless due to bone marrow infiltration with lymphoma. * Patient has a calculated or measured creatinine clearance of \<20 mL/minute within 14 days before registration. (Creatinine Clearance is indicated through the Serum Creatinine. If the Serum Creatinine is abnormal, the physician may then due a 24 hour urine to further clarify Creatinine Clearance. A 24 hour urine test is not required per study.) * Patient has ≥ Grade 2 peripheral neuropathy within 14 days before registration. * Myocardial infarction within 6 months prior to registration or has New York Heart Association (NYHA) Class III or IV heart failure. uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Hypersensitivity to bortezomib, boron or mannitol. * Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant * Patient received other investigational drugs with 14 days before registration * Serious medical or psychiatric illness likely to interfere with study participation * Diagnosed or treated for another malignancy within 3 years of registration, w/ the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy. * CNS involvement with lymphoma. * Known HIV-positive. * History of disease refractory to a purine analog (defined as remission duration of \< 6 months to therapy that included fludarabine, pentostatin, or cladribine). * History of intolerance of bortezomib, boron, mannitol, cladribine, or rituximab. * Patient has \> 1.5 X ULN Total Bilirubin * Radiation therapy within 3 weeks before randomization. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
* Rituximab 375 mg/m2 IV day1 * Cladribine 4 mg/m2 IV over 2 hours days 1-5 * Bortezomib 1.3 mg/m2 IV days 1 and 4 * Repeat every 28 days for a maximum of 6 cycles
intervention Names
Drug: rituximab
Drug: bortezomib
Drug: cladribine
label
VCR (Velcade, Cladribine and Rituximab)
type
EXPERIMENTAL

interventions

arm Group Labels
VCR (Velcade, Cladribine and Rituximab)
description
375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
name
rituximab
other Names
Rituxan
type
DRUG
arm Group Labels
VCR (Velcade, Cladribine and Rituximab)
description
1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
name
bortezomib
other Names
Velcade
type
DRUG
arm Group Labels
VCR (Velcade, Cladribine and Rituximab)
description
4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
name
cladribine
other Names
Leustatin
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 24
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
PFS was calculated from the first dose of study drug to the first documentation of disease progression, death regardless of cause, or change in therapy due to disease progression, whichever occurred first. If disease progression did not occur by the end of treatment, patients were evaluated every 3 months until progression with physical examination, laboratory studies, and conventional computed tomographic imaging, up to a maximum of 2 years. The Kaplan-Meier product-limit method will be used to estimate progression-free survival in the presence of censoring.
measure
Progression-free Survival at 2 Years
time Frame
2 years

secondary Outcomes

measure
Overall Survival at 2 Years
time Frame
2 years
measure
Complete Response Rate
time Frame
Two years
measure
Partial Response
time Frame
Two years

Full study description

brief Summary: RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with cladribine and rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine and rituximab works in treating patients with advanced mantle cell lymphoma or indolent lymphoma.
detailed Description: OBJECTIVES: Primary * Determine the 2-year progression-free survival of patients with advanced mantle cell lymphoma or indolent lymphoma treated with bortezomib, cladribine, and rituximab. Secondary * Determine the 2-year overall survival of patients treated with this regimen. * Determine the complete response and overall response rate in patients treated with this regimen. * Describe the long- and short-term toxicity of this regimen in these patients. * Determine the prognostic importance of Aurora kinase A in patients treated with this regimen. * Determine the cytokine profiles for each lymphoma subtype and how they change with this regimen. * Evaluate the prognostic importance of major carcinogenic pathways using tissue microarray. OUTLINE: Patients receive bortezomib IV on days 1 and 4, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and after course 1 for cytokine profile studies. Previously collected tissue samples are obtained for analysis of Aurora kinase A and B, Ki-67, cyclin D, Bcl-2, phosphor-HisH3, c-Met, and VEGF expression by using tissue microarray (IHC staining), reverse transcriptase-PCR, and/or western blotting. After completion of study therapy, patients are followed up every 3 months for 2 years.

Source references

references

citation
Puvvada SD, Guillen-Rodriguez J, Kumar A, Inclan L, Heard K, Rivera XI, Anwer F, Schatz JH, Mahadevan D, Persky DO. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19.
pmid
29056470
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-e464df1f5d76b3bd153e
requested nct id
NCT00980395
primary nct id
NCT00980395
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
02e7d0370330529912b4b8211ceb6f83b3f915625b23cda63a1460f8590791b7
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-e464df1f5d76b3bd153e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00980395
occurrences
context exact
NCT00980395
end
11
exact text
NCT00980395
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/313/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
7dabf6d87b3e706d1d1f67f2e28a586c2bc30f28393e9761f9d73278bf588ac3
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice